Avenarius, Matthew R.
Huang, Ying
Kittai, Adam S. http://orcid.org/0000-0002-4891-6144
Bhat, Seema A.
Rogers, Kerry A.
Grever, Michael R.
Woyach, Jennifer A. http://orcid.org/0000-0002-3403-9144
Miller, Cecelia R. http://orcid.org/0000-0001-6110-6069
Article History
Received: 1 February 2024
Revised: 5 February 2024
Accepted: 7 February 2024
First Online: 19 February 2024
Competing interests
: ASK receives research funding from AstraZeneca and BeiGene, and has consulted for Abbvie, AstraZeneca, Beigene, BMS, Kite/Gilead, Janssen, and LOXO@Lilly, and is on the speaker’s bureau for BeiGene. SAB consulted for Pharmacyclics, Janssen, BeiGene, and AstraZeneca; received an honorarium from OncLive; and received a travel grant from ArQule. KAR receives research funding from Genentech, AbbVie, and Novartis and consults for Pharmacyclics, Janssen, Genentech, Abbvie, AstraZeneca, BeiGene, LOXO@Lilly, and Alpine Immune Science. MRG consults for Astra Zeneca, Pharmacyclics, Ascerta, Axio. Receives research funding from Hairy Cell Leukemia Foundation for Patient Data Registry, travel funding from Hairy Cell Leukemia Foundation and scientific honorarium from University of Pittsburgh. Serves as Board Chair for Scientific Board for Hairy Cell Leukemia Foundation (no reimbursement). JAW receives research funding from Karyopharm Therapeutics, Loxo@Lilly, Schrodinger, AbbVie, and MorphoSys, and consults for ArQule, AstraZeneca, BeiGene, Janssen, Pharmacyclics, Newave, AbbVie, MorphoSys, and Genentech. CRM receives funding from AbbVie. The remaining authors declare no competing interests.